Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ArcticZymes Technologies Director's Dealing 2010

Feb 22, 2010

3538_dirs_2010-02-22_703b6030-2f3d-4e29-a632-4833aeaf4d5c.html

Director's Dealing

Open in viewer

Opens in your device viewer

Notification of trade primary insider

CSO of Biotec Pharmacon, Dr. Rolf E. Engstad, has

today purchased 50,000 shares in the Company at an

average price of NOK 4.09 per share.

Dr. Engstad holds 111,133 shares after this

transaction.